<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01284582</url>
  </required_header>
  <id_info>
    <org_study_id>AFF007</org_study_id>
    <nct_id>NCT01284582</nct_id>
  </id_info>
  <brief_title>Safety, Immunogenicity and Dose Response of ATH03, a New Vaccine Against the Cholesterol Ester Transfer Protein (CETP)</brief_title>
  <official_title>Safety, Immunogenicity and Dose Response of ATH03, a New Vaccine Against the Cholesterol Ester Transfer Protein (CETP), in Healthy Male Subjects With High Density Lipoprotein Cholesterol (HDLc) Blood Concentrations Equal or Below 80 mg/dl</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Affiris AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Affiris AG</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 1 Study :Safety, Immunogenicity and Dose response of ATH03, a new vaccine against the
      cholesterol ester transfer protein (CETP), in healthy male subjects with high density
      lipoprotein cholesterol (HDLc) blood concentrations equal or below 80 mg/dl.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This open-label Phase 1 study will be conducted in three groups of 12 subjects with HDLc
      blood concentrations equal or below 80 mg/dl at a single study center. 36 subjects will be
      enrolled.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of adverse events</measure>
    <time_frame>264 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>264 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response to the various applied doses of ATH03</measure>
    <time_frame>264 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>HDL</condition>
  <condition>Drug Safety</condition>
  <arm_group>
    <arm_group_label>ATH03 Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ATH03, 10 µg, 0.2% Alum</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ATH03 Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ATH03, 30 µg, 0.2% Alum</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ATH03 Group C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ATH03, 100 µg, 0.2% Alum</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ATH03</intervention_name>
    <description>4 vaccinations</description>
    <arm_group_label>ATH03 Group A</arm_group_label>
    <arm_group_label>ATH03 Group B</arm_group_label>
    <arm_group_label>ATH03 Group C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy males

          -  High density lipoprotein cholesterol (HDLc) blood concentrations equal or below 80
             mg/dl

        Exclusion Criteria:

          -  Clinically relevant pathological findings
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Achim Schneeberger, MD</last_name>
    <role>Study Director</role>
    <affiliation>Affiris AG</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department for Clinical Pharmacology Medical University Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 25, 2011</study_first_submitted>
  <study_first_submitted_qc>January 26, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2011</study_first_posted>
  <last_update_submitted>October 4, 2012</last_update_submitted>
  <last_update_submitted_qc>October 4, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 5, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CETP</keyword>
  <keyword>Vaccine</keyword>
  <keyword>Cholesterol</keyword>
  <keyword>Inhibition</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

